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1. Introduction 
Inflammatory bowel disease (IBD), comprising of Crohn's disease (CD) and ulcerative colitis 
(UC), is a kind of chronic relapsing disorder of unknown etiology, which is characterized 
clinically of abdominal pain, diarrhea, weight loss, fever, as well as endoscopic, radiologic, 
histopathologic findings and biochemical changes (e.g. perinuclear anti-neutrophil cytoplasm 
antibody (p-ANCA), anti-Saccharomyces cerevisiae antibody (ASCA) and IBD-specific p-
ANCA markers) (Veluswamy et al., 2010).  
IBDs have been shown to be involved with potential factors such as genetic, immunologic, 
bacterial, and environmental elements; the relative strength of these factors and the 
importance of their interplay remain largely unknown (Edwards et al., 2008). Differences in 
incidence rates across age, time, and geographic areas suggest that environmental factors 
are involved in IBD, while only cigarette smoking and appendectomy have consistently 
been identified as risk factors (Colombel et al., 2007). Familial aggregation of IBD showed by 
an epidemiological study first suggested that genetic factors might play an important role in 
the pathogenesis of IBD. In 2001, the first CD susceptibility gene, NOD2/CARD15 on 
chromosome 16, was characterized. The gene identification should help us to understand 
the complex interaction between the environment and the intestinal immune system. 
The previous studies of IBD led to a complex overall impression of the disease, with some 
described patterns in disease prevalence. IBD was considered to be more frequent in the 
developed countries especially Northern Europe and the United States, usually of colder 
climates with increased incidence as distance from the equator increases. But now, IBD is 
increasingly reported in non-classical populations and in developing regions such as Asia, 
the Mid-East and Africa. More recent data showed significantly higher prevalence in Asians 
and time trend studies described an increasing trend in the incidence of UC and a similar 
but lower rise in CD (Goh & Xiao, 2009). 
The epidemiological changes that are taking place mirror the experience of Western 
countries 50 years ago. And the changes seem to occur in parallel with the rapid 
socioeconomic developments in Asia. It appears that certain racial groups among Asians 
who are more susceptible to IBD and who will demonstrate a higher frequency of IBD when 
exposed to putative environment. 
In recent years, with the improvement of living standard, the global incidence and prevalence 
are increasing year by year, which has seriously affected quality of life all over the world. 
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Because IBDs are chronic, life-long immunologic disorders that frequently require 
hospitalization or surgery. Such hospitalizations account for a significant portion of the 
estimated USD 6 billion in healthcare costs annually for IBD in the USA (Cappelman et al., 2008).  
With regards to the treatments of IBD, it mainly focuses on two aims, one is to induct the 
ease of acute outbreak; and another is to maintain the alleviation (Domènech, 2006). The 
traditional drugs used for IBD mainly include 5-aminosalicylic acid, glucocorticoid, and 
immune inhibitors. In recent years, with the deeper understandings of IBD immunity 
mechanism, more biological agents have been introduced in the treatment and they have 
brought new dawn for IBD patients. The advantages of new biological agents in the 
treatment of IBD spark the clinical debate between the traditional Set-Up way and the new 
Set-Down strategy (Baert et al., 2007).  
Clinically apparent malnutrition is more frequent among IBD admissions than those of non-
IBD admissions. Its association with greater mortality and resource utilization may reflect 
more severe underlying disease that may lead to both malnutrition and worse outcomes. 
Nevertheless, diagnosable malnutrition may serve as a clinical marker of poor IBD 
prognosis in hospitalized patients (Nguyen et al., 2008). Therefore, nutrition support for IBD 
patients plays an important role in the treatment of IBD (Cao et al., 2005).  Many previous 
studies have focused on different aspects of nutrition support, such as nutritional 
immunology, nutrition pharmacology and so on. The results of the current meta-analysis 
and multicenter randomized controlled clinical studies have lead to the conclusions that 
nutrition support especially the enteral nutrition support may induce illness ease, promote 
mucosal healings, and help maintaining the long-term stability of the disease. 
Numerous studies from Europe and North America have provided a wealth of information 
regarding the epidemiological and clinical characteristics of IBDs in Caucasians. While large 
clinical material of IBD in China is still limited. The aim of this study is to systematically 
provide a relatively intact image of IBD patients in our hospital during the past 9 years, 
which may also be a valuable reference of the situation in China. The reason why we 
choosing this period of time is because April 2003 was the start of clinical application of 
double balloon enteroscopy (DBE) in our hospital, and then was also the start when the 
diagnostic yield of Crohn’s Disease in our hospital significantly increased.  
2. Patients and methods 
2.1 Study population and data collection 
The data source of this study was from Shanghai Rui Jin Hospital another from May 2002 to 
December 2010. It covered all hospitalized IBD patients during a period of 9 years from 
department of gastroenterology, department of surgery and department of pediatrics. The 
diagnosis of IBD adhered to the criteria of Lennard-Jones (Lennard-Jones, 1989). Rui Jin 
Hospital is a tertiary level and first-class public hospital, it serves a well-defined catchment 
population in Shanghai. Over 96% of the medical care is provided by the public hospital 
system in this district. About 30% of the hospitalized patients were from the nearby 
provinces and all over China. 
The total hospitalization number enrolled in this retrospective study was 769.The following 
data were collected and analyzed among the patients: the demographic characteristics 
(mainly included age and gender), the duration of the disease at diagnosis, the inspection 
methods used for diagnosis, the location of the lesions involved, the lab data of the patients, 
and the treatments followed by the convinced diagnosis (medical treatments and/or 
surgical treatments). 
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The DBE devices used in the study were manufactured by Fujinon (EN 450P5/20, EN 
450T5/20; Fujinon Inc, Saitama, Japan). 
2.2 Statistical analysis 
We adopt the hierarchical analysis method. All the IBD in-patients during the last 9 years 
were divided into 3 groups according to the time when they were hospitalized: May 2002 to 
December 2004 as Group 1, January 2005 to December 2007 as Group 2, January 2008 to 
December 2010 as Group 3. The study made a longitudinal comparison among the 3 groups, 
and also made a horizontal comparison between the CD group and the UC group according 
to the statistical results. 
Data analysis was performed using SPSS 17.0 statistical software package (SPSS Inc., 
Chicago, USA). Continuous variables were summarized using means and standard 
deviations, while categorical variables were expressed as proportions. Variables were 
compared with the chi-square test. P value <0.05 was judged of statistical difference, while 
<0.01 was judged of significantly statistical difference. 
3. Results 
3.1 Demographic characteristics 
Overall, a total number of 769 hospitalized IBD patients were included in this study. 
Among them, 536 patients suffered CD (69.7%) and 233 patients suffered UC (30.3%),  
the percentage of CD was significantly higher than that of UC. Mean ages at diagnosis 
were 36.8±15.4 years old (range 2-88 years) in CD and 44.9±17.3 years old (range 3-83 
years) in UC patients. The gender ratio (male/female) was 1.60 in CD and 1.28 in UC, 
there existed no statistical difference between these two groups (p>0.05). The mean 
duration of CD at first hospitalization was 5.6±4.7 years (1-70 years), of UC was 5.8±3.8 
years (1-25 years).  
 
 
Group 
CD (n=536) UC (n=233)  
Sum. 
 
Num. 
(male: female) 
Mean age Num. 
(male: female) 
Mean age 
Group 1 
(2002-2004) 
76 
( 46:30) 
42.6±15.2 69 
(35:34) 
50.0±16.4 145 
Group 2 
(2005-2007) 
186 
(119:67) 
39.5±15.1 71 
(42:29) 
46.9±14.7 257 
Group 3 
(2008-2010) 
274 
(166:108) 
33.4±14.9 93 
(54:39) 
39.5±18.5 367 
Total 536 
(331:205) 
36.8±15.4 233 
(131:102) 
44.9±17.3 769 
Table 1. Comparison of demographic characteristics among 3 groups 
For each stratified period, the results were showed in Table 1. As we could see, the 
diagnosed numbers of both CD and UC increased with the year, while the ages at diagnosis 
were decreased. Number of male patients was more than that of female patients in both 
diseases in each group. 
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3.2 Diagnostic modalities 
With the development and clinical applications of novel techniques for small bowel 
inspection, such as double balloon enteroscopy (DBE), multisliced CT enterography 
(MSCTE) and capsule endoscopy (CE), the diagnostic yield of IBD significantly increased in 
our hospital during the past decade.  
 
 
Group 
MSCTE Enteroscopy CE 
CD
(%) 
UC
(%) 
CD
(%) 
UC
(%) 
CD
(%) 
UC 
(%) 
1 4/76 
(5.3) 
7/69 
(10.1) 
74/76 
(97.4) 
66/69 
(95.7) 
7/76 
(9.2) 
0/69 
2 67/186 
(36.1) 
6/71 
(8.5) 
168/186 
(90.3) 
65/71 
(91.5) 
22/186 
(11.8) 
1/71 
(1.4) 
3 210/274 
(76.6) 
23/93 
(24.7) 
266/274 
(97.1) 
88/93 
(94.6) 
35/274 
(12.8) 
2/93 
(2.2) 
Table 2. Panorama of diagnostic modalities applied in IBD during 2002-2010 
The panorama of diagnostic modalities applications was summarized in Table 2. 
Enteroscopy (in the current study, both colonoscopy and DBE were included) was still the 
major diagnostic modality in IBD identification. Application of MSCTE became quite 
common both in CD and UC during year of 2008-2010 (Group 3), the total percentages of 
patients accepted MSCTE examines raised up to 63.5% (233/367) in all IBDs. Meanwhile, it 
was revealed that the use of CE was still limited in our hospital. 
And we also analyzed the number of patient undertaken more than one single inspection: 
double inspections and all 3 inspections in different time groups (Tab. 3). In our hospital, the 
costs of each inspection method were: RMB 300 for colonoscopy, RMB 2,600 for 
antegrade/retrograde DBE, RMB 1,100 for MSCTE and RMB 2,800 for CE. Though a 
combination of different inspections may help increasing diagnostic yield, the high expense 
restricted its clinical application.  
 
 
Inspection  
Group 1 Group 2 Group 3 
CD (%)
(n=76) 
UC (%)
(n=69) 
CD (%)
(n=186) 
UC (%)
(n=71) 
CD (%)
(n=274) 
UC (%) 
(n=93) 
Double 12(15.8) 3(4.3) 31(16.7) 2(2.8) 103(37.6) 17(18.3) 
Triple 4(5.3) 0 0 0 0 0 
Table 3. Trends of modality combination during the year of 2002-2010 
Figure 1 showed the trends of application of enteroscopy, MSCTE, and CE in CD patients 
during 2002 to 2010. Figure 2 showed the situation in UC. In the histograms, intuitive 
situation could be observed. During the year of 2008 to 2010, MSCTE became a screening 
method for CD patients, the application ratio was up to 76.6%. 
3.3 Anatomic extent 
In this study, we adopted a special scoring method to evaluate the anatomic extent. We 
scored 1 when the lesion only involved rectosigmoid colon, ileocecal or one segment of 
small intestine; scored 2 when the lesion extended up to left-sided colon, and scored 3 when  
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Fig. 1. Application of MSCTE, enteroscope, and CE in CD patients during the retrospective 9 
years 
 
 
Fig. 2. Application of MSCTE, enteroscope, and CE in UC patients during the retrospective 9 
years 
the lesion extensively involved the whole length of the colon and/or multiple segments  
of the small intestine. Then the number of patients of each scoring group was summarized, 
respectively (Tab. 4).  
As we can see, in Group of Score 1, CD was significantly more than UC (p=0.000<0.001), 
which indicated that the anatomic extent of CD is relatively limited comparing with that of 
UC. While in Group of Score 3, the situation was just the opposite (p=0.000<0.001), UC was 
more likely to involve extensively. 
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Score CD (%) UC (%) X2 P value 
1 393 (73.3) 137 (58.8) 15.991 0.000 
2 85 (15.9) 44 (18.9) 1.065 0.302 
3 58 (10.8) 52 (22.3) 17.511 0.000 
Total number 536 233   
Table 4. Comparison of anatomic extent in CD and UC 
3.4 Laboratory index 
Although there are a lot of laboratory parameters believed to have certain relations with  
the severity of IBDs, the accurate role of each item remains controversial. In the present 
study, we observed 3 laboratory indexes with more confirming evidence of the clinical 
value. They are PLT, ESR (erythrocyte sedimentation rate) and CRP (C reactive protein). The 
criteria of each index were judged according to that of our hospital. PLT concentration 
higher than 300*109/L, ESR level exceeded 30mm/s, CRP over 0.8mg/L were judged of 
abnormal. 
Primarily research and clinical experience have presented that patients with IBD suffer 
higher risk of colonic cancer comparing with normal population, thus IBD patients should 
under the surveillance of tumor marker in order to provide information of the possibility of 
advancing cancer. Therefore, we also evaluated 3 tumor markers (CEA, CA-125 and CA-199) 
in all the patients. 
According to the results (Tab. 5), we had a rough impression that both ESR level and CRP 
level were higher in CD than in UC in Group 2 and Group 3. While other lab index showed 
no obvious difference between CD and UC in all 3 groups. 
 
 
Lab Index 
Group 1 Group 2 Group 3 
CD (%) 
(n=76) 
UC (%) 
(n=69) 
CD (%) 
(n=186) 
UC (%) 
(n=71) 
CD (%) 
(n=274) 
UC (%) 
(n=93) 
PLT 
(>300*109/L) 
26 (34.2) 24 (34.8) 96 (51.6) 36 (50.7) 164(59.9) 29 (31.2) 
ESR 
(>30 mm/s) 
28 (36.8) 19 (27.5) 142(76.3) 38 (53.5) 143(52.2) 34 (36.6) 
CRP 
(>0.8 mg/L) 
12 (15.8) 12 (17.4) 161(86.6) 33 (46.5) 163(59.5) 21 (22.6) 
CEA 
(>5 ng/ml) 
8 (10.5) 0 12 (6.5) 2 (2.8) 6 (2.2) 0 
CA-125 
(>35 U/ml) 
9 (11.8) 0 71 (38.1) 31 (43.7) 33 (12.0) 7 (7.5) 
CA-199 
(>35 U/ml) 
0 6 (8.7) 11 (5.9) 8 (11.3) 7 (2.6) 6 (6.5) 
Table 5. Comparison of lab index abnormalities between CD and UC in 3 groups 
3.5 Clinical manifestation 
Patients with IBD usually manifest similar clinical features, but each individual may  
have his own characteristic. And for CD and UC, the patterns of clinical manifestation  
are different in some aspect. The major clinical manifestations observed in the study 
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included abdominal mass, abdominal pain, mucous stool, hematochezia, fever (higher 
than 39°C), small bowel obstruction (SBO), anal fistula, weight loss, surgical intervention 
and parental manifestations (PM). Parental manifestations mainly included uveitis, 
episcleritis, stomatitis, erythema nodosum, pyoderma gangrenosum, peripheral arthritis 
and etc.  
The result turned out that the ratios of SBO (p=0.000<0.01), anal fistula (p=0.000<0.01) and 
weight loss (p=0.008<0.01) in CD were significantly higher than in UC, abdominal pain 
(p=0.036<0.05), surgical intervention (p=0.025<0.05) and parental manifestations 
(p=0.043<0.05) also occurred more in CD patients. On the other hand, UC patients were 
much more common with mucous stool (p=0.000<0.01) and hematochezia (p=0.000<0.01) 
(Tab. 6). 
 
Clinical 
manifestation 
CD (n=536) 
(%) 
UC (n=233) 
(%) 
X2 P value 
Abdominal pain 436 (81.34) 177 (75.9) 4.399 0.036 
Abdominal mass 17 (3.17) 3 (1.29) 2.276 0.131 
Mucous stool 103 (19.22) 133 (57.08) 109.468 0.000 
Hematochezia 175 (32.65) 191 (80.93) 158.415 0.000 
Fever 143 (26.68) 59 (25.32) 0.154 0.694 
SBO 56 (10.45) 5 (2.15) 15.326 0.000 
Anal fistula 45 (8.39) 1 (0.43) 18.326 0.000 
Weight loss 210 (39.18) 68 (29.18) 7.028 0.008 
Surgery 51 (9.51) 11 (4.72) 5.035 0.025 
PM 29 (5.41) 5 (2.15) 4.096 0.043 
Table 6. The clinical manifestation observed in all 769 IBD patients 
3.6 Medical treatment 
At the moment, medical treatment of IBD mainly included four kinds of pharmaceuticals:  
5-aminosalicylic acid (5-ASA) or sulfasalazine, corticoids, immunosuppressant (we use 
azathioprine in our hospital), and tumor necrosis factor monocolonal antibody. 
5-ASA or sulfasalazine was a base-line agent wildly used in mild IBD patients or used for 
maintenance therapy. For those IBD patients of active stage, we prescripted 4g/day of this 
kind of medicine. And the maintenance dosage dropped to 2g/day. Short-term 
intravenous or oral corticosteroid treatment was used in moderate-to-severe IBD patients. 
Methylprednisolone given intravenously usually start from the dosage of 40-60mg/day, 
and 7-10 days later, we changed to corticoids via oral route. The whole treatment course 
with corticoids was usually tapered within 12-25 weeks. Azathioprine was used as a 
second-line agent for corticosteroid-dependent or corticosteroid-refractory individuals. It 
was also used as the replacement therapy during the course of corticosteroid tapering. As 
for Infliximab, it only began to be used in CD and UC since 2008 and 2009 respectively. 
Infliximab was listed in China in September 2007, and was mainly used in IBD patients 
suffered from fistula or in those with corticosteroid- and/or immunosuppressant- 
refractory. 
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Fig. 3. Medical treatments for CD during 2002-2010 
 
 
Fig. 4. Medical treatments for UC during 2002-2010 
The overview situation of the usage of four pharmaceuticals stated above in CD patients 
from 2002 to 2010 was shown in Figure 3. As we could see, 5-ASA/ sulfasalazine was 
always a base-line agent used in most patients (range from 70% to 97.6%). The percentages 
of patients using corticoids became rather stable since the year of 2006, about half of the 
hospitalized CD patients had the records of using corticoids. The same trend of AZA could 
be observed since the year of 2007. And that of UC was listed in Figure 4. 5-
ASA/sulfasalazine also played an important role in treating UC, 94.2% to 100% patients 
were given the agent during 2006-2010. Since 2006 to 2010, the corticoids were also applied 
to more than half of UC patients; the data was a little bit higher than that of CD patients 
(63.1% vs 55.06%). The application of AZA was a little bit lower than that in CD. In 2010, 
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Infliximab is more commonly used in CD patients (especially complicated with fistula) than 
in UC patients. 
An interesting phenomenon could be observed was the change of corticoids using in both 
diseases. From the year of 2002 to 2005, the trends of corticoids application were just in the 
opposite directions in CD and UC. In CD, it turned out to be a raising curve; while in UC, 
the ratio dropped from 80% to 47.4%. But after that, since the year of 2006, in both diseases 
the use of corticoids became stable.  
3.7 Repeated-hospitalization 
Within all the 769 patients, 195 individuals had experiences of repeated-hospitalization 
(25.36%). 148 were CD and 47 were UC, accounted for the total number of each group 
27.61% (148/536) and 20.17% (41/233), respectively. In CD cohort, 80 were male (54.1%) and 
68 were female (45.9%). As for UC, 29 were male (61.7%) and 18 were female (38.3%).  
The times of repeated-hospitalization ranged from 2 to 22. Detailed information was listed 
in Table 7. The reasons for repeated-hospitalization mainly included intestinal obstruction, 
severe  GI bleeding, high temperature (>39°C) difficult to control, fistula, etc. 
 
Times 2 3 4 5 >=6 Sum. 
N 109 35 15 18 18* 195 
* Within these 18 patients, 8 were hospitalized for 6 times, 3 for 7 times, 1 for 8 times, 2 for 9 times, 2 for 
14 times, 1 for 15 times and 1 for 22 times.  
Table 7. Overview of repeated-hospitalization 
The interval between every 2 hospitalizations ranged from 0-94 months. And the mean 
interval of UC was longer than that of CD (Tab. 8). 
 
 Mean interval (m) Range (m) 
CD (n=148) 6.29±10.71 0-92 
UC (n=47) 10.04±15.39 0-94 
Total (n=195) 6.94±12.13 0-94 
Table 8. Overview of intervals between every 2 hospitalizations 
4. Discussion 
Significant changes have been observed in the epidemiology of IBD in the last two decades. 
Traditionally, the incidence of IBD was higher in the developed, industrialized countries; as 
for CD it ranged from 0.7/105 to 11.6/105 and for UC from 2.0/105 to 14.3/105. In contrast, 
nowadays it became more prevalent in the previously low incidence areas such as 
developing countries. In particular, the incidence and prevalence of IBD increased 
significantly in the Asia-Pacific region in recent years. Several recent studies confirmed that, 
in Asia, the prevalence of CD is 3.6/105 to 7.7/105，and of UC is 4.0/105 to 44.3/105; the 
morbidity of CD ranges from 0.5/105 to 1/105, of CD the data is between 1/105 and 2/105 
(Leong et al., 2004; Al-Ghamdi et al., 2004).  In China, it is inferred that the prevalence may 
be 1.4/105 for CD, and 11.6/105 for UC. The difference of clinical epidemiology, diagnosis 
and treatment between Asia-Pacific IBDs and that of western countries may be contributed 
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to the diversities of environment, genetic background and medical systems. Lakatos et al 
reported , the incidence of UC in developing countries is similar to that observed in North 
America and Western Europe, while the incidence of CD is still relatively low, suggesting 
that the environmental factors may act faster or differently in UC than in CD (Lakatos L & 
Lakatos PL, 2007). 
As stated before, Rui Jin Hospital affiliated to Shanghai Jiao Tong University is a tertiary 
level and first-class hospital, which is one of the largest public hospitals in China. This 
retrospective study enrolled all 769 hospitalized IBD patients from three departments in our 
hospital from May 2002 to December 2010. Thus, we can take it into granted that the current 
study, for the first time, systematically provide a relatively intact image of IBD patients in 
Shanghai during the past 9 years, which is also a valuable reference of the whole situation in 
China. 
Grossly, our study revealed that the prevalence of IBD in Shanghai gradually increased 
during the observing 9 years. The potential explanations for the increasing trend may be at 
least partially contributed to the popularity of western life style and diet habits in recent 
years. As we can see, with the development of economic, literature, as well as tourism, 
international interactions are more frequent, therefore the gap of environment, diet habit, 
and life style becomes lessen. The phenomenon that changes of life style and diet habit 
paralleling with the change of IBD prevalence also indicates the importance of environment 
mechanism in IBD.  
A second reason that may also contributed to the increasing of diagnostic yield of IBD is the 
improvement of inspection methods. As mentioned before, since 2003 when the DBE, 
MSCTE and CE became more and more popular in clinical application in our hospital, the 
diagnostic ratio of IBD also increased obviously. CE is a painless procedure that enables 
visualization of the entire small bowel and is highly acceptable to both doctors and patients. 
The disadvantages and limitations of this diagnostic modality include disability to control 
the direction, the random nature of the images, and the lack of a facility for sampling. The 
high cost of CE in China also precludes its use as a first-line diagnostic modality for small 
bowel disease. DBE was regarded as a revolutionary development for the diagnosis of small 
bowel diseases (Zhong et al., 2007). The entire small bowel could be visualized, usually with 
a combination of antegrade and retrograde approaches. DBE is used as a gold standard 
diagnostic modality for small bowel disease. MSCTE serves as a screening method now 
days in our hospital, when the relatively low cost of this modality taken into account. We 
failed to take enteroclysis into account, since we conducted it only in little amount of 
patients.  
Nevertheless, differ from other previous studies; our team reported a significantly higher 
prevalence of CD than that of UC. Among the total of 769 IBD patients enrolled in this 
study, 536 (69.7%) were suffered from CD and 233 (30.3%) were suffered from UC. Mean 
age at diagnosis in UC patients was older than in CD, duration of each disease didn’t show 
much difference. Male patients were more than female patients in both diseases in each 
time-stratifying group. The main reason could be that CD involved small bowel easily, and 
the three novel inspection techniques mentioned above largely developed the blind spots in 
small bowel. And that may also give a reasonable explanation why it was the diagnostic 
yield of CD not the UC rose significantly. 
We chose several relatively special serologic targets in this retrospective study in IBD. The 
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laboratory indexes observed included: the number of PLT, the level of CRP and ESR, tumor 
markers (CEA, CA-125, CA-199). In our study, there existed no obvious differences of the 
CRP and/or ESR between UC group and CD group. Both markers were higher in CD than 
in UC. As for tumor indicators, CA-125 and CA-199 seemed to have some abnormal 
tendency comparing with normal population. But further and detailed research is necessary 
before getting more convinced conclusions. 
With the invention and development of immunomodulators and biologics, obvious 
changes have been introduced into IBD treatment in the past decade. Infliximab, a 
chimeric monoclonal antibody against tumor necrosis factor alpha, was first approved for 
the treatment of CD in 1998 (Hanauer et al., 2002; Sands et al., 2004; Targan et al., 1997); 
subsequently, three other biologic agents (Adalimumab, Certolizumab and Natalizumab) 
became available for induction and maintenance of remission in CD (Colombel et al., 
2007; Feagan et al., 2008; Sandborn et al., 2007). Infliximab is the only biologic agent 
approved for the treatment of UC after demonstrating success in the ACT I and ACT II 
trials. In China, Infliximab was not listed until September 2007. We are now using it in 
more IBD patients in 2011, but since the clinical data of this year is not included within the 
current study, we have little to discuss here.  
As for immunosuppressive agents (such as azathioprine, methotrexate, and 6-
mercaptopurine), many studies during the last ten years have focused on their application 
in the treatment of both UC and CD (Ananthakrishnan et al., 2010; Cosnes et al., 2005). 
Azathioprine was used as a second-line agent for corticosteroid-dependent or corticosteroid-
refractory individuals. And in our experience, it was more used as the replacement therapy 
during the course of corticosteroid tapering. Patient was usually asked to start using AZA 
two weeks before corticosteroid tapering at the dosage of 10 mg/day. 
The goals of IBD therapies can be summarized as: inducing remission, preventing 
complications, improving life quality, and reducing hospitalization as well as surgical rates 
(Bai & Peng, 2010). Thus, predicting of disease outcome is of great importance. Chow and 
his team reported that thrombocytosis in IBD patients at diagnosis predicted corticosteroid-
dependency, structuring phenotype of CD and presence of anaemia in UC predicted 
subsequent course of corticosteroid refractoriness (Chow et al., 2009). In the further research, 
we will convince the conclusion by collecting and analyzing the related data.  
With regard to relapsing, for hospitalized IBD patients, repeated-hospitalization may be 
looked on as an indicator. In our current study, about 1/5 patients suffered relapse within a 
mean interval about 7 months. The patients hospitalized for more than 6 times were mostly 
for treatment with Inflixmab. As for the predictive factors of relapse, is the defect of this 
retrospective study. We will do more detailed work in our future research. 
There are several limitations in our current study. First, we could not eliminate the 
possibility of referral bias. For the hospitalized IBD patients were in moderate-severe 
situations, which means patients suffer mild IBD may be cared by outpatient department. So 
the conclusion of this study maybe more reliable in reflecting the situation of moderate-
severe patients. Second, the important marker of disease activity, CDAI, was not captured in 
this study, that would be the part included in our further study. Last but not least, data of 
some patients were not intact. The nutrition support, especially the enteral nutrition 
support, may induce illness ease, promote mucosal healings, and help maintaining the long-
term stability of the disease. The lack of this part is also a pity. Nutrition therapy in patients 
with IBD is probably both undervalued and underused. Maybe we could try to make up for 
it in our future prospective study. 
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5. Conclusion  
At present, large clinical material in IBD is still limited in Chinese population. This study, 
for the first time, systematically provided a relatively intact image of hospitalized IBD 
patients in Shanghai. The result is also a valuable reference of the whole situation in China. 
In summary, in this 9-year retrospective study, an increasing prevalence of IBD in Shanghai 
was observed, which is synchronized with that in the western countries. The changes of life 
style and diet habits, the improvement of diagnostic modalities may play important role in 
it. We have more options, such as biologics, for IBD treatment besides the traditional 
medicine of 5-ASA, corticosteroids and immunosuppressants. The combination and 
adjustment of medicine are of great significance in inducing remission and maintaining the 
long-term stability of the disease. To choose appropriate diagnostic modality for patients, to 
establish effective surveillance indexes, and to develop individualized treatment program 
will contribute much to pharmacoeconomics. 
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